MICHAEL BEST STRATEGIES LLC

Lobbying for SAREPTA THERAPEUTICS · Medical research and drug development company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · House · Senate · $110,000.00 income · posted Oct 20, 2025

Lobbying activity 2

Health Issues

Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy

Medical/Disease Research/Clinical Labs

Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.